Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.

Date publication

octobre 2024

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr EYMARD Jean-Christophe , Dr MOUILLET Guillaume , Dr LORGIS Véronique

Tous les auteurs :
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39448350

Résumé

Avelumab first-line maintenance treatment was approved for patients with advanced urothelial carcinoma (aUC) without progression following platinum-based chemotherapy (PBC), based on the results from the JAVELIN Bladder 100 phase 3 trial.

Mots clés

Avelumab, Bladder cancer, Immune checkpoint inhibitor, Immunotherapy, Maintenance, Observational study, Real world, Urothelial carcinoma

Référence

Eur Urol Oncol. 2024 10 23;: